No Data
No Data
Tempest to Participate in Upcoming Investor Conferences
PDF Version BRISBANE, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-m
Express News | HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Tempest Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 1368.75% HC Wainwright & Co. → $47 Reiterates Buy → Buy 03/20/2024 1368.75% HC Wainwright & Co.
Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)
Buy Rating Affirmed for Tempest Therapeutics Amidst Promising Clinical Advancements
Tempest Therapeutics | 10-Q: Quarterly report
No Data
jbcs : I bought because I liked the company and I really thought it could go somewhere I really wish it would pop. Maybe someday.